LA JOLLA, Calif., April 17, 2009 -- Burnham Institute for Medical Research (Burnham) is pleased to announce that five of its postdoctoral fellows will present seven papers on their data at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009. In addition, John C. Reed, M.D., Ph.D., Burnham President and CEO, Professor and Donald Bren Presidential Chair, will chair a panel on Apoptosis-based Strategies for Cancer Therapy, where he will also present his own research.
This year's meeting, being held in Denver from April 18 to 22, will highlight the best cancer science and medicine from institutions all over the world. In addition to Dr. Reed, Burnham researchers presenting at the AACR meeting include:
- Lilach Agemy, Ph.D., who will present Nanoparticle-induced Vascular Blockade in Prostate Cancer.
- Jason Garrison, Ph.D., who will discuss ARTS and Siah Collaborate in a Novel Pathway for XIAP Degradation
- Shi Ranxin, Ph.D., who will present two papers: Cyclosporin A Sensitizes Cancer Cells to Death Receptor-Mediated Apoptosis and Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NFκB Activation Induced by Protein Kinase C and Antigen Receptors.
- Changming Fang, Ph.D., who will also present two papers: Ileal Bile Acid Binding Protein Mediates the Chemopreventative Effect of Ursodeoxycholic Acid by Activating Nuclear Receptor FXRα in Colorectal Cancer and Genetic Deletion of FXRα Promotes Colon Tumorigenesis in ApcMin/+ Mice
- Adam Richardson, Ph.D., will present The Role of Pentose Phosphate Pathway in the Warburg Effect.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top-four institutions nationally for NIH grant funding and among the top-25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public benefit corporation. For more information, please visit www.burnham.org.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research.